DGAP-Adhoc: BB Biotech AG publishes its interim report

2019. július 19., péntek, 07:00





DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report


BB Biotech AG publishes its interim report


19-Jul-2019 / 07:00 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Media release of July 19, 2019



Interim report of BB Biotech AG as at June 30, 2019



BB Biotech AG publishes its interim report



BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2019, which covers the results of its business activities for the first six months of 2019.



Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2019 amounted to CHF 554 mn (loss of CHF 70 mn in H1 2018). For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.



BB Biotech AG"s interim report as at June 30, 2019 can be downloaded at www.bbbiotech.com.




For further information:



Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch



Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch



TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, Tel. +41 79 423 22 28

Thomas Egger, teg@te-communications.ch

www.bbbiotech.com



Company profile

BB Biotech AG invests in companies in the fast growing market of biotechnology and is one of the world"s largest investors in this sector.

BB Biotech AG is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech AG"s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.



Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech AG, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech AG and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech AG and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.











19-Jul-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

























Language: English
Company: BB BIOTECH AG

Schwertstrasse 6

8200 Schaffhausen

Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID: 842989





 
End of Announcement DGAP News Service




842989  19-Jul-2019 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=842989&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.